October 17, 2019
Sensorion has the last patient’s last visit in SENS-111 phase 2 clinical trial
Out of 105 patients were enrolled and treated in Sensorion’s SENS-111 Phase 2 trial, the last patient’s last visit of…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
October 16, 2019
Roche reports 10% rise in group sales for nine months 2019
Roche on Wednesday reported 10% raise in sales in the third yearly quarter of 2019, backed by new products, while its Pharmaceuticals Division sales went up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta.
October 16, 2019
Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CFTM 1)
-Boehringer Ingelheim is enrolling first patient to test nvestigational compound BI ENaC inhibitor delivered twice daily via the Respimat, a…
October 16, 2019
Bicycle Therapeutics presents data for its lead Bicycle Toxin Conjugate (BTC) product candidate
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC) a clinical-stage biotechnology company pioneering a new and differentiated class of…
October 16, 2019
Amarna Therapeutics Raises €10 million to Progress lead Development Candidate into Clinical Trials and Appoints a new Supervisory Board
Amarna Therapeutics has raised €10 million in a round led by Swedish investor Flerie Invest AB with substantial contributions from…
October 16, 2019
NOXXON enrolls first patient in phase 1/2 testing combo of NOX-A12 with radiotherapy in newly diagnosed brain cancer
NOXXON said Wednesday it has enrolled the first patient in phase 1/2 trial in a therapy of increasing doses of…
October 16, 2019
Ipsen, Blueprint Medicines in licence deal for BLU-782 for the treatment of Fibrodysplasia Ossificans progressiva (FOP)
Ipsen and Blueprint medicines have entered a deal which expands Ipsen’s rare diseases portfolio to include BLU-782, a highly selective…
October 15, 2019
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal…
October 15, 2019
Trialbee and TriNetX Partner to Accelerate Patient-Centric Clinical Trials
MALMÖ, Sweden & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Trialbee, a world-leading technology provider in patient matching and engagement, is partnering with…
October 15, 2019
Numab Appoints Daniel Vasella to Board of Directors
PFÄFFIKON, Switzerland–(BUSINESS WIRE)–Numab Therapeutics AG today announced that effective October 1 it has appointed former Novartis CEO and Chairman Dr.…